Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study

被引：23

作者：

Moskowitz, Alison J. ^{[1
]}

Advani, Ranjana H. ^{[2
]}

Bartlett, Nancy L. ^{[3
]}

Vose, Julie M. ^{[4
]}

Ramchandren, Radhakrishnan ^{[5
]}

Feldman, Tatyana A. ^{[6
]}

LaCasce, Ann S. ^{[7
]}

Christian, Beth A. ^{[8
]}

Ansell, Stephen M. ^{[9
]}

Moskowitz, Craig H. ^{[10
]}

Brown, Lisa ^{[11
]}

Taft, David ^{[11
]}

Ansari, Sahar ^{[11
]}

Zak, Daniel E. ^{[11
]}

Sacchi, Mariana ^{[12
]}

Manley, Thomas ^{[11
]}

Herrera, Alex F. ^{[13
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA

[2] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA

[3] Washington Univ, Sch Med, St Louis, MO USA

[4] Univ Nebraska Med Ctr, Div Hematol Oncol, Omaha, NE USA

[5] Karmanos Canc Inst, Detroit, MI USA

[6] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[7] Dana Farber Canc Inst, Boston, MA 02115 USA

[8] James Canc Hosp, Columbus, OH USA

[9] Mayo Clin, Rochester, MN USA

[10] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[11] Seattle Genet Inc, Bothell, WA USA

[12] Bristol Myers Squibb, Princeton, NJ USA

[13] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-122576

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

238

引用

页数：8

共 50 条

[41] Long-term follow-up of zimberelimab in relapsed or refractory classic Hodgkin lymphoma: Insights from the phase II YH-S001-04 clinical trial
Kan, Suisui
Bai, Hai
Liu, Hui
Cui, Jie
Ke, Xiaoyan
Zhang, Huilai
Liu, Lihong
Yan, Dongmei
Jiang, Yongsheng
Zang, Aimin
Qi, Junyuan
Wang, Li
Liu, Zhuogang
Xu, Bing
Zhang, Ying
Zhang, Zhihui
Zhao, Xielan
Hu, Chunhong
Yang, Shenmiao
Zhou, Hui
Shi, Jinsheng
Shao, Zonghong
Xiang, Ying
Lin, Ningjing
Zhang, Mingzhi
LEUKEMIA RESEARCH, 2025, 149
[42] Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
Yuqin Song
Quanli Gao
Huilai Zhang
Lei Fan
Jianfeng Zhou
Dehui Zou
Wei Li
Haiyan Yang
Ting Liu
Quanshun Wang
Fangfang Lv
Haiyi Guo
Liudi Yang
Rebecca Elstrom
Jane Huang
William Novotny
Vivian Wei
Jun Zhu
Leukemia, 2020, 34 : 533 - 542
[43] Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
Song, Yuqin
Gao, Quanli
Zhang, Huilai
Fan, Lei
Zhou, Jianfeng
Zou, Dehui
Li, Wei
Yang, Haiyan
Liu, Ting
Wang, Quanshun
Lv, Fangfang
Guo, Haiyi
Yang, Liudi
Elstrom, Rebecca
Huang, Jane
Novotny, William
Wei, Vivian
Zhu, Jun
LEUKEMIA, 2020, 34 (02) : 533 - 542
[44] Long-Term Responders after Brentuximab Vedotin: Experience on 57 Patients with Relapsed and Refractory Hodgkin and Anaplastic Large Cell Lymphoma
Zinzani, Pier Luigi
Gandolfi, Letizia
Casadei, Beatrice
Pellegrini, Cinzia
Broccoli, Alessandro
Derenzini, Enrico
Quirini, Federica
Tonialini, Lorenzo
Cavo, Michele
Argnani, Lisa
Stefoni, Vittorio
BLOOD, 2015, 126 (23)
[45] LONG-TERM RESPONDERS AFTER BRENTUXIMAB VEDOTIN: EXPERIENCE ON 57 PATIENTS WITH RELAPSED AND REFRACTORY HODGKIN AND ANAPLASTIC LARGE CELL LYMPHOMA
Gandolfi, L.
Celli, M.
Pellegrini, C.
Casadei, B.
Morigi, A.
Stefoni, V.
Broccoli, A.
Quirini, F.
Tonialini, L.
Argnani, L.
Cavo, M.
Zinzani, P. L.
HAEMATOLOGICA, 2015, 100 : 3 - 3
[46] Long-term survival outcomes of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis
Wang, Z.
Sun, K.
Zhu, Z-M
Zhang, P.
Yang, J.
Yang, S-W
Zheng, M-Q
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (07) : 2941 - 2948
[47] Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial (vol 36, pg 1428, 2018)
Armand
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (26) : 2748 - 2748
[48] Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Pro, Barbara
Advani, Ranjana H.
Brice, Pauline
Bartlett, Nancy L.
Rosenblatt, Joseph D.
Illidge, Tim
Matous, Jeffrey V.
Ramchandren, Radhakrishnan
Fanale, Michelle A.
Connors, Joseph M.
Yang, Yin
Kennedy, Dana A.
Shustov, Andrei R.
BLOOD, 2012, 120 (21)
[49] Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): Long-term follow-up efficacy and safety results from a phase 2 study.
Song, Yuqin
Gao, Quanli
Zhang, Huilai
Fan, Lei
Zhou, Jianfeng
Zou, Dehui
Li, Wei
Yang, Haiyan
Liu, Ting
Wang, Quanshun
Lv, Fangfang
Guo, Haiyi
Yang, Liudi
Huang, Jane
Novotny, William F.
Wang, Yidi
Zhu, Jun
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[50] The role of autologous stem cell transplantation in primary refractory and relapsed Hodgkin lymphoma - a long-term follow-up single center experience
Roerden, M.
Soekler, M.
Kanz, L.
Bethge, W.
Vogel, W.
Walz, J.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 163 - 163

← 1 2 3 4 5 →